In this study, we preliminarily clarified the positive correlation of FPR2 and RhoA in ovarian cancer cells, and a RhoA inhibitor reversed the migration ability of EOCs, which was promoted by ectopic expression of FPR2. The gene discussed is FPR2; the disease is ovarian carcinoma.